A Study of TAS-120 in Patients With Metastatic Breast Cancer
Summary
The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used either alone or in combination with the hormonal therapy, fulvestrant. This study will be conducted in patients with metastatic breast cancer who have specific Fibroblast Growth Factor Receptor gene abnormalities and who have previously received conventional therapies to treat their breast cancer, or who are not able to tolerate certain cancer therapies. This study will also evaluate the safety of taking futibatinib, or futibatinib and fulvestrant, by learning about the potential side effects.
Timeline
- Start
- 2020-01-28
- Primary completion
- 2023-05-31
- Completion
- 2023-09-06
Outcome
Outcome not reported
Stopped (Business): “The Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Futibatinib | Small molecule | 20 mg | Oral |